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ABSTRACT
Objective To investigate the cost-effectiveness of a 
modified form of cognitive behavioural therapy (CBT) for 
recurrent non-cardiac chest pain.
Methods We tested the effectiveness and cost-
effectiveness of a modified form of CBT for chest pain 
(CBT-CP)(4–10 sessions) in patients who attended 
cardiology clinics or emergency medical services 
repeatedly. Patients were randomised using a remote web-
based system to CBT-CP or to standard care in the clinic. 
Assessments were made at baseline and at 6 months and 
12 months. The primary outcome was the change in the 
Health Anxiety Inventory Score at 6 months. Other clinical 
measures, social functioning, quality of life and costs of 
services were also recorded.
Results Sixty-eight patients were randomised with low 
attrition rates at 6 months and 12 months with 81% of 
all possible assessments completed at 6 months and 
12 months. Although there were no significant group 
differences between any of the outcome measures at 
either 6 months or 12 months, patients receiving CBT-CP 
had between two and three times fewer hospital bed days, 
outpatient appointments, and A&E attendances than those 
allocated to standard care and total costs per patient were 
£1496.49 lower, though the differences in costs were 
not significant. There was a small non-significant gain in 
quality adjusted life years in those allocated to CBT-CP 
compared with standard care (0.76 vs 0.74).
Conclusions It is concluded that CBT-CP in the context of 
current hospital structures is not a viable treatment, but is 
worthy of further research as a potentially cost-effective 
treatment for non-cardiac chest pain.
Trial registration number ISRCTN 14711101.
INTRODUCTION
Non-cardiac chest pain has the status of a 
medical diagnosis in the 10th Revision of 
the International Classification of Diseas-
es(ICD-10)(R07.89- non-cardiac chest pain) 
but shares this diagnosis with 20 other 
synonyms under the general heading of 'other 
chest pain' and is highly heterogeneous. 
It includes a range of disorders including 
a general description only (non-cardiac 
chest pain, atypical chest pain, non-specific 
chest pain), muscular tension (chest pain, 
musculoskeletal, chest pain, tightness, muscu-
loskeletal chest pain), pain generated in other 
structures apart from the heart (sternal chest 
pain, chest wall pain, localised chest pain) 
and pain related to exertion (exertional chest 
pain, chest pain on exertion). None of the 
diagnostic labels include any indication of a 
psychological component, even though there 
is abundant literature on psychological inter-
ventions for the condition.1–3
Despite this lack of attribution, it is 
suspected that a substantial proportion of 
patients with non-cardiac chest pain have 
psychological causes, or at least can be 
treated appropriately using psychological 
means. Possible causes include excessive 
health anxiety (termed illness anxiety in the 
5th Revision of the American Diagnostic 
Statistical Manual (DSM-5 4), one or more 
variants of somatic symptom disorder, the 
former diagnosis of hypochondriasis, and 
obsessive compulsive disorder. But because 
these diagnoses are given by mental health 
professionals, and not by the physicians who 
make the diagnosis of non-cardiac chest 
pain, they are seldom recorded in practice. 
Health anxiety has recently been associated 
with a future ischaemic heart disease in the 
general population over 12 years even when 
known risk factors for cardiovascular disease 
are controlled for.5 Health anxiety is also 
associated with adverse cardiac events in 
those who had myocardial infarction over the 
subsequent 4 years.6 Therefore health anxiety 
may be important to recognise and treat in its 
own right because of poor cardiac outcomes. 
Thus, despite good evidence that most of 
the people who present with non-cardiac 
chest pain do not have heart disease,7 8 we do 
not know how many have physical causes or 
precipitants and how many have psycholog-
ical ones.
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Previous work has suggested that many of these patients 
can be treated successfully in a relatively short number 
of sessions with different forms of cognitive behavioural 
therapy (CBT). Two findings gleaned from randomised 
trials are noteworthy. The effects of treatment are rela-
tively modest, rapidly achieved but short-lasting (with 
maximal benefit at 3 months and usually lost by 6 
months), and the number of patients who are potentially 
eligible for trial inclusion far exceeds those who actually 
take part.9 In planning a new trial on the basis of new 
evidence of a modified form of treatment10 we therefore 
wished to maximise the recruitment rate, have a longer 
period of follow-up, and to try and select patients with 
psychological causes for their chest pain.
METHOD
The design of the COPIC (Cognitive therapy for Pain 
In the Chest) study was a simple two-treatment parallel 
design with equal allocation to either an adapted form 
of CBT for chest pain (CBT-CP) or to standard care 
in the relevant NHS services. The randomisation was 
carried out by an independent clinical trials unit (Health 
Services Unit, CHaRT, University of Aberdeen) with 
equal allocation to CBT and ST, with initial help given 
from Open-CDMS, a similar independent unit.
Inclusion and exclusion criteria
Inclusion criteria were (1) significant chest pain on at least 
two separate occasions in the past year in which no signif-
icant pathology explaining the symptoms was found, (2) 
signed consent to take part in the study, (3) age between 18 
years and 75 years. The exclusion criteria were (1) under 
active psychiatric care, (2) having received a prescription 
of a new psychoactive drug within the previous 2 months, 
(3) receiving, or on waiting list for, a formal psychological 
treatment. Those who were currently stable and on regular 
psychoactive medication (for more than 2 months) were 
eligible for the study. By seeing patients who had presented 
more than once in the past year it was hoped that a more 
resistant cohort would be recruited with less likelihood of 
non-specific  improvement.
Assessments
It was not clear which psychopathology would be most 
prominent in these patients, but because health anxiety 
had been found to be a common feature in many patients 
presenting to cardiology clinics,10 the change in scores on 
the short form of the Health Anxiety Inventory (HAI)11 
was chosen as the primary outcome.
A more specific outcome, but not one that had 
previously been validated, was the Health Anxiety 
Questionnaire12 adapted for Chest Pain (Lucock and 
Morley Health Anxiety Questionnaire – Chest Pain 
(LMHAQ-CP), which included special questions on 
chest pain agreed with the original authors. The orig-
inal Health Anxiety Questionnaire was also being used as 
the primary outcome in a parallel study in Christchurch, 
New Zealand, and so it was felt important to be included. 
Other assessments included self-completed analogue 
ratings of both the frequency and severity of chest pain 
and discomfort developed with the aid of a patient (Inskip 
Scale)(Appendix), self-ratings of generalised anxiety and 
depression (using the Hospital Anxiety and Depression 
Scale (HADS Scale),13 and social functioning using the 
KEY QUESTIONS
What is already known about this subject?
 ► We searched PubMed from 1  January 1996 to 31  December 
2015, using the search terms ‘non-cardiac chest pain’, ‘non-
specific chest pain *” and ‘atypical chest pain *”, with no language 
restrictions. We identified four systematic reviews from the same 
Cochrane group published between 2005 and 2015, the last being 
an update of all previous reviews.
 ► The 2015 review identified a total of 17 randomised controlled 
trials with 1006 randomised participants. Although the review 
suggested that psychological interventions, mainly using a 
cognitive-behavioural approach, were of some value in reducing 
chest pain and chest pain frequency, this was shown only in 
the first 3 months following the intervention and lost between 
3 months and 12 months. Three of the studies were judged to have 
a high risk of outcome bias and there was high heterogeneity in the 
data. The authors concluded that there were ‘modest to moderate 
benefit for psychological interventions, particularly those using a 
cognitive-behavioural framework, which was largely restricted to 
the first 3 months after the intervention.’ They also suggested that 
further randomised controlled trials of psychological interventions 
for non-specific chest pain with follow-up periods of at least 12 
months were needed.
What does this study add?
 ► By selecting a population that had at least two episodes of non-
cardiac chest pain within the previous year we had a population 
that was less likely to remit spontaneously and have greater 
pathology. We also included a cost-effectiveness element, unlike 
any of the previous studies, and this showed that our treatment 
led to fewer outpatient appointments, A & E attendances, and 
fewer occupied bed days, accompanied by some cost savings. 
We extended assessment to 12 months after randomisation and 
although there were no significant group differences, the benefits 
at 12 months with cognitive behavioural therapy (CBT) compared 
with standard care were greater than at 6 months, unlike other 
trials. The lack of significant benefit was a consequence of the 
trial being underpowered, and we have concluded that the failure 
to recruit was for reasons that are linked to the current attitudes 
towards the management of chest pain in the hospital system, 
rather than the absence of suitable patients willing to take part. 
Further randomised trials are best carried out using a stepped 
care approach with a multidisciplinary team of psychological and 
medical personnel.
How might this impact on clinical practice?
 ► We conclude that there is little to be gained by further trials of this 
subject unless the structure of current services is changed. Before 
patients with non-cardiac chest pain are referred for CBT or any 
other psychological treatment there needs to be an integrated 
assessment involving psychological and physical components to 
ensure homogeneity and exclusion of those with transient or other 
non-cardiac symptomatology.
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Social Functioning Questionnaire.14 The Schedule for 
Evaluating Persistent Symptoms (SEPS),15 that had been 
found in preliminary studies to be an accurate measure 
of medically unexplained symptoms, was also included. 
Quality of life was recorded using the Euroqol Quality 
of Life Scale (EQ-5D scale16) at 6 months and 1 year. In 
addition, all health service related costs were recorded 
using the Adult Service User Schedule17 in the 6 months 
before randomisation and at 6-month intervals subse-
quently until 1 year. Using these data the overall costs for 
patients in the two arms of the trial were compared as 
well as major cost items such as inpatient care.
Target number of participants
From previous work with the HAI we calculated that a 
difference between the scores of 4 between two groups 
at follow-up is clinically significant. Using data from an 
unrelated randomised controlled trial of CBT in health 
anxiety18 we demonstrated a significant benefit between 
CBT and control with a sample of 49 patients. In this study 
with a standard deviation (SD) for the change of HAI at 
1 year as 6.0 a sample size of 96 patients would have 90% 
power to demonstrate significance at the two-sided 5% 
significance level.
Ethics and consent
All patients recruited to the study read a brief informa-
tion sheet initially and randomly discussed with clinical 
staff involved in their care. Those that consented were 
then seen by a research assistant, who gave each person 
a full participant information sheet and explained the 
study. If, after full assessment and explanation, patients 
agreed to take part, a signed declaration of informed 
consent was completed. 
Procedure
Initially the trial was confined to Kings Mill Hospital, 
North Nottinghamshire but because of poor recruit-
ment was subsequently extended to The Royal Berkshire 
Hospital in Reading and The Hillingdon Hospital in 
Middlesex after appropriate ethical amendments.
Patients satisfying the criteria for inclusion and lacking 
exclusion criteria who presented with chest pain to either 
cardiology clinics, acute medicine and/or accident and 
emergency departments at the three hospitals above were 
considered for the study. Two other centres were included 
by agreement but the lack of a local principal investigator 
prevented recruitment from ever starting. The proce-
dures for the chest pain pathway are not the same at these 
three hospitals but are still likely to be representative of 
the UK as in most hospitals there is no standard pathway 
for the assessment of non-cardiac chest pain unless rapid 
access chest pain clinics are available.
Avoidance of bias
Concern has been expressed that bias may have been 
present in previous trials because single-blind assessment 
was prevented by trial protocols.9 Because of this all asses-
sors made assessments without any discussion of treatment 
and if for any reason allocation was disclosed at interview 
a different researcher was involved in future assessments.
Randomisation
Patients identified as eligible for the trial by cardiology 
and accident and emergency staff, and willing to take 
part, were first assessed by an independent research 
assistant. After baseline assessment all ratings and demo-
graphic details are recorded on a secure online database, 
initially Open-CDMS (Open Source Clinical Data 
Management System) in London and from 2014, CHaRT 
(Centre for Healthcare Randomised Trials) in the Health 
Services Research Unit, University of Aberdeen. Patients 
were then allocated to either CBT-CP or standard care in 
permuted stacked blocks and stratified by study centre. 
The allocated treatment was then passed to the trial coor-
dinator (SC) who, if the patient was allocated to CBT-CP, 
informed the next available therapist at the centre 
concerned and then the patient, GP and consultant. 
Patients allocated to standard care are informed by letter 
or phone call and the GP and hospital team also notified. 
Follow-up assessments were carried out by research assis-
tants who were ignorant of the original allocation after 6 
months and 12 months.
Experimental interventions CBT-CP
This was given by nursing staff and psychologists trained 
and supervised by HT. The procedure initially was a modi-
fication of CBT for health anxiety (CBT-HA)19 and its 
essential features were linked to health anxiety, including 
a formulation made for a recent episode of chest pain, 
assessment of the behaviours that appeared to be main-
taining the pain, building up a model of the cognitive 
theory of emotion with illustrations where necessary of 
the nature of symptoms and using the patient's strengths 
in finding alternative strategies of dealing with chest pain. 
It was also felt important to check that any gains made 
were consolidated and, where they were not, to empha-
sise techniques of relapse prevention before finishing 
treatment, not least because of previous evidence that 
gains in other studies were not maintained.9 When it was 
found that health anxiety was not a prominent feature 
in the presentation the focus shifted to examining other 
underlying fears and worries and changing the format of 
sessions. These included anxieties about vulnerability to 
assault, extreme exhaustion after chest pain and the fear 
that some important pathology would be missed if assess-
ment was not made urgently. These often only became 
apparent later in therapy. According to our planned 
protocol20 between 4 and 10 sessions were offered but 
some flexibility was allowed as in our previous study up to 
15 sessions were needed in more complex cases.10
Standard care
No change was made to the form of care given to the 
patients allocated to this group in either their primary 
or secondary care settings. Thus, at various times care 
involved appropriate testing, explanation of findings, 
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reassurance and the opportunity for the patient to ask 
questions about the symptoms and the test results. These 
interventions were made by the relevant clinicians and not 
influenced by the trial investigators. GPs were informed 
about the allocation of each patient after randomisation 
but received no further information subsequently.
Primary and secondary outcomes
The primary outcome was the reduction in scores on the 
HAI between baseline and 6 months. Although previous 
studies have recorded outcomes at 3 months we did 
not think all psychological treatment would have been 
completed by then so did not record at this time point. 
Secondary outcomes were (1) the reduction in visual 
analogue scores of frequency and intensity of chest pain, 
(2) reduction in LMHAQ-CP scores, (3) reduction in 
the total SEPS Score, (between baseline and 6 months 
and 1 year, (4) the number of attendances at Accident & 
Emergency Departments after 6 months and 1 year, (5) 
total health service costs in primary and secondary care 
at 6 months and 12 months, (6) reduction in generalised 
Figure 1 CONSORT diagram. CBT-HA, cognitive behavioural therapy for health anxiety.
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anxiety symptoms (on the HADS-Anxiety Scale after 6 
months and 1 year, (7) reduction in depressive symptoms 
on the HADS-Depression Scale at the same time points 
and (8) change in mean LMHAQ-CP scores from base-
line after 1 year.
Statistical analysis
All analyses were by intention to treat, analysed as 
randomised. The primary analysis compared mean 
change scores of the HAI Scale from the baseline to 
6 months between the treatment and control groups. 
Multilevel modelling (MLM)was used to estimate and 
test differences of mean change scores between the two 
comparison groups' adjustment for baseline score.21 
22 Centre influence on treatment effect estimates 
was initially controlled during modelling but results 
without adjusting centre influence were presented 
given the small patient samples.23 Missing values were 
imputed under missing at random assumption with 
REALCOME software.24 MLM was also performed with 
observed only data to check the robustness of treat-
ment effect estimates sensitive to missingness. Analyses 
of secondary outcomes followed the same analytical 
procedure and statistical approaches. Stata V.14 was 
used for data   analysis.
Economic evaluation
The economic evaluation adopted a health and social 
care perspective by collecting all the service use data over 
the period of follow-up, and so allowing the total cost of 
the services used by each study participant to be summed. 
These costs were taken together with the cost of the CBT 
to generate the average costs for each randomised group. 
The costs were compared using standard t-tests, recom-
mended for economic analysis as they allow for analysis 
of mean costs without transformation. The robustness 
of this approach was checked through the calculation of 
bootstrapped CIs.25 26 A limited cost-effectiveness anal-
ysis was also performed where the costs in the CBT-CP 
and ST groups were compared alongside the difference 
in quality adjusted life years (QALYs) derived from the 
EQ-5D scores.
RESULTS
Only 68 patients (47 M; 21 F) were recruited to the study 
in the 30 months between July 2012 and December 
2014; this included a 9-month extension. As the study 
was underpowered greatly, significant group differences 
were neither expected nor found. Thirty-four patients 
each were randomised to the two groups. Attrition 
rates were low, with only 26 (19%) of the 136 possible 
follow-up points missing (figure 1). The mean number 
of treatment sessions in the CBT-CP group was 5.7 (range 
0–15), carried out over a mean period of 14.3 weeks (SD 
8.78). The longer period of treatment was sometimes 
necessary as there was considerable comorbidity. In 
the CBT-CP group 12 (35%) of the patients had other 
pathology (5 with previous cardiac disease indepen-
dent of present symptomatology, 2 with gastrointestinal 
pathology probably linked to the chest pain (irritable 
bowel syndrome and gastric reflux), 2 with other psycho-
pathology (chronic fatigue syndrome and post-traumatic 
stress disorder) and 3 with sexual health problems). 
One patient disclosed the nature of the allocation to the 
research worker during follow-up. Subsequently further 
assessments on this patient were made by an indepen-
dent researcher.
The primary outcome was the change in HAI Scores 
at 6 months. This was probably an error in selection. 
Most patients (63%) did not have HAI Scores at or above 
the pathological level of 20 (table 1). At 6 months these 
scores showed greater improvement in the standard care 
arm (3.29, 95% CI −5.63 to –0.95) than the CBT-CP arm 
(2.35 95% CI −4.58 to –0.12), but the opposite effect was 
shown at 12 months (SC 4.21 95%CI −6.73  to –1.69; 
CBT-CP 4.97 95%CI−7.41 to –2.54).
Although none of the treatment differences were 
significant (table 2) it was notable that for almost every 
measure there was greater improvement in the CBT-CP 
group than for standard care at 12 months compared with 
6 months (table 2). The LMHAQ-CP showed the greatest 
differences between CBT-CP and standard care at 12m 
(mean difference 4.36, 95% CI −9.60 to 0.87, p=0.1).
Table 1 Baseline information
Variable
Standard 
Care (n=34) CBT(n=34)
Age, years: mean(SD) 48.71 (13.46) 48.91 (14.50)
Centre: n(%)
  Notts 14 (41.8) 14 (41.8)
  Hillingdon  7 (20.59)  6 (17.65)
  Berks 13 (38.24) 14 (41.18)
Gender: n(%)
  Male 24 (70.59) 23 (67.65)
  Female 10 (29.41) 11 (32.35)
Ethnicity: n(%)
  White British 29 (85.29) 24 (70.59)
  Others  5 (14.71) 10 (29.41)
HAI: mean(SD) 16.29 (8.45) 18.13 (8.50)
HADS-Anx: mean(SD)  8.53 (4.81)  9.53 (4.43)
HADS0Dep: mean(SD)  5.01 (3.71)  6.12 (4.26)
SFQ: mean(SD)  4.56 (3.57)  5.16 (3.69)
EQ-5D: mean(SD)  7.79 (1.53)  7.03 (1.71)
HAQ-CP:mean(SD) 19.97 (12.80) 23.13 (12.53)
Pain frequency: mean(SD)  3.62 (1.46)  3.32 (1.87)
Pain severity: mean(SD)  5.41 (2.28)  6.24 (2.44)
SEPS symptoms: mean(SD)  5.79 (1.45)  5.85 (1.64)
SEPS mean: (SD) 14.97 (4.27) 16.21 (5.15)
No. of patients HAI≥20(%) 10 (29.41) 15 (44.12)
CBT, cognitive behavioural therapy; HADS, Hospital Anxiety 
and Depression Scale; HAI, Health Anxiety Inventory; HAQ-CP, 
Health Anxiety Questionnaire for Chest Pain; SEPS, Schedule 
for Evaluating Persistent Symptoms; SFQ, Social Functioning 
Questionnaire.
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Economic analysis
Economic data were obtained on all patients at base-
line, 85% at 6 months (85%) and 76% at 12 months 
follow-up. For full analysis 50 of the 68 patients were 
used (74%).
Over 12 months there was an observable difference in 
the use of hospital services between randomised groups; 
on average participants in the CBT group had fewer 
nights as inpatients and less than half as many outpatient 
appointments and Accident & Emergency (A&E) atten-
dances as those in the standard care group (table 3). The 
use of community services was similar in both groups. The 
CBT-CP intervention cost on average was £480 per partici-
pant. The between-group differences in hospital service use 
is reflected in the cost of these services over follow-up. The 
CBT-CP group used on average £1771.52 less in hospital 
services, which more than covered the cost of the CBT-CP 
(table 4). Thus the average cost of all services over follow-up 
was £2235.53 in the CBT-CP group compared with £3732.02 
in the standard care group. The difference was not statisti-
cally significant, largely because of a wide scatter of scores 
(p=0.798).
The utility scores, as measured using the EQ-5D 
were broadly similar and improved over time in both 
groups. There was a small and non-significant higher 
QALY over follow-up in the CBT group (0.76 QALYs) 
compared with the TAU group (0.74 QALYs) (table 5). 
Considering costs and outcomes together, the CBT-CP 
intervention resulted in lower overall costs and better 
outcomes.
Table 2 Results of multilevel modelling of change score (95% CI) from baseline and group difference (95% CI)
Standard care (n=34) 
Mean change from
baseline (95% CI)
CBT (n=34) Mean change 
from baseline (95% CI)
Group comparison 
Change difference
(95% CI) p value
HAI*
  6 months −3.29 (−5.63 to to 0.95) −2.35 (−4.58 to to 0.12)  0.94 (−2.30 to  4.17) 0.569
  12 months −4.21 (−6.73 to to 1.69) −4.97 (−7.41 to to 2.54) −0.76 (−4.11 to 2.59) 0.654
HADS_anx
  6 months −2.39 (−3.80 to to 0.99) −2.99 (−4.27 to 1.71) −0.60 (−2.55 to 1.35) 0.546
  12 months −3.08 (−4.49 to to 1.67) −4.15 (−5.65 to to 2.66) −1.07 (−3.19 to 1.05) 0.319
HADS_dep
  6 months −0.69 (−1.86 to 0.48) −0.96 (−2.15 to 0.23) −0.27 (−1.91 to 1.38) 0.75
  12 months −1.57 (−2.77 to 0.38) −1.99 (−3.23 to 0.75) −0.41 (−2.15 to 1.32) 0.639
SFQ
  6 months −0.75 (−1.94 to 0.43) −0.52 (−1.64 to 0.61)  0.24 (−1.39 to 1.86) 0.774
  12 months −0.22 (−1.42 to 0.98) −0.94 (−2.17 to 0.29) −0.72 (−2.55 to 1.11) 0.435
HAQ-CP
  6 months −3.31 (−6.48 to 0.14) −5.75 (−9.00 to 2.50) −2.44 (−7.21 to 2.32) 0.313
  12 months −5.16 (−8.67 to 1.66) −9.53 (−12.93 to 6.12) −4.36 (−9.60 to 0.87) 0.101
INSKIP pain
  6 months −1.08 (−1.64 to 0.52) −0.43 (−0.97 to 0.10)  0.65 (−0.11 to 1.40) 0.095
  12 months −1.47 (−2.07 to 0.88) −1.40 (−1.99 to 0.80)  0.08 (−0.71 to 0.87) 0.842
INSKIP severity
  6 months −0.72 (−5.73 to 4.30) −4.00 (−9.12 to 1.12) −3.29 (−10.57 to 4.00) 0.376
  12 months −0.60 (−5.60 to 4.41) −4.39 (−9.59 to 0.82) −3.79 (−11.07 to 3.49) 0.307
Seps1symp
  6 months −0.84 (−1.66 to to 0.02) −0.38 (−1.12 to 0.37)  0.46 (−0.63 to 1.55) 0.407
  12 months −0.76 (−1.51 to 0.00) −1.03 (−1.76 to to 0.30) −0.27 (−1.30 to 0.76) 0.605
SEPS2 mean
  6 months −2.76 (−4.69 to 0.82) −2.93 (−5.01 to 0.85) −0.17 (−2.83 to 2.49) 0.898
  12 months −3.80 (−5.85 to 1.76) −4.69 (−6.97 to 2.41) −0.88 (−3.94 to 2.17) 0.568
*Subgroup analysis of the high versus low HAI group (in table 1) showed no important differences between the four groups so identified and 
HAI scores were all lower at 12 months than at 6 months.
CBT, cognitive behavioural therapy; HAI, Health Anxiety Inventory; HADS-A, Anxiety section of Hospital Anxiety and Depression Scale; 
HADS-D, Depression section of Hospital Anxiety and Depression Scale; HAQ-CP, Health Anxiety Questionnaire for Chest Pain; SFQ, Social 
Functioning Questionnaire, INSKIP scale names after its inventor, Brian Inskip. 
Pain measured in terms of frequency and severity by INSKIP scales, SEPS, Schedule for Evaluating Persistent Symptoms; SEPS1 (frequency 
of main symptoms), SEPS2 (disability produced by main symptoms).
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DISCUSSION
The most unusual feature of this trial is that, despite 
addressing a very common problem in clinical practice, 
only 68 patients were recruited from three sites over a 
30-month period. We are not in a position to determine 
why the recruitment rate was so low and are not sure how 
many eligible patients did not take part, but from the 
partial data we collected only about 20% of those who 
could have taken part, did so. In spite of this, those that 
did take part were adherent to treatment and had low 
levels of dropout, so it was clearly the recruitment uptake 
that was the main problem (accentuated by reluctance 
of cardiologists in three other centres to take part in the 
study despite ethical approval). As the trend for improve-
ment was in favour of CBT-CP for almost all measures at 
12 months, if the study had been adequately powered the 
results might have been different.
Our study represents the first trial of psychological 
treatment for non-cardiac chest pain to include a robust 
economic evaluation. The reduction in frequency of 
attendance at accident and emergency department, in 
outpatient clinics and in use of bed days, were notable 
in the CBT-CP group and illustrate the reduced demand 
on services that follows treatment. Between-group 
differences in costs were not significant, but the study was 
not designed with sufficient statistical power to detect 
them.
Guidance for future research on this subject
During the course of this study it has been very apparent 
that the way in which services are currently configured 
do not allow psychological treatments to be adequately 
assessed. This is clear from previous studies; high levels 
of failure to recruit eligible patients and high dropout 
rates are prominent. A recent Cochrane review of psycho-
logical treatment for non-cardiac chest pain examined 
the effect of psychological interventions in a total of 17 
randomised controlled trials involving 1006 participants. 
Despite these many studies the overall conclusion is 
tentative and of limited benefit to clinicians; ‘this review 
suggests a modest to moderate benefits of psycholog-
ical interventions, particularly those using a cognitive 
behavioural framework, which was largely restricted to 
the first three months after the intervention’.9 Just over 
half of eligible patients agreed to take part and in the five 
largest studies, including 331 patients, the dropout rates 
ranged between 28% and 57%.
The previous studies have taken place over a period of 
more than 20 years and, not surprisingly, do not appear 
to have influenced practice except in a few centres. It is 
also of some concern that, when benefit has been shown, 
it is of such limited duration, and could be deemed not 
worthy of service adoption. The results of the COPIC 
Study should be seen in this context. Despite its inability 
to recruit an adequate number of patients, the results 
using CBT-CP suggest that the intervention was adding 
more than standard CBT, with economic benefits main-
tained over 1 year.
It is relevant that the supervisor of all the therapists in 
the study (HT) was a medically qualified doctor who had 
been employed in both primary and secondary care as well 
as having well developed skills in CBT. This allowed her to 
detect several other additional pathologies (oesophageal 
reflux, chronic fatigue syndrome, post-traumatic stress 
disorder), contributing to the non-cardiac chest pain, 
that would probably not have been detected by a psychol-
ogist or other therapist just trained in CBT. Five patients 
had previous cardiac pathology that had to be separated 
Table 3 Mean (SD) use of healthcare services by 
randomised groups over 12 months follow-up
Standard 
(n=25)
CBT-CP 
(n=25)
Mean (SD) Mean SD
Number of CBT sessions 0.00 (0.00) 5.72 3.49
Inpatient (nights) 3.20 7.16 1.12 3.05
Outpatient (appointments) 3.80 5.71 1.80 2.38
Day case (procedures) 0.12 0.33 0.32 0.69
Accident and emergency 
(attendances)
3.36 9.36 1.20 1.61
Diagnostic tests (number) 0.12 0.33 0.32 0.69
Community health and social care 
services (number)
6.40 17.03 3.76 6.64
CBT-CP, cognitive behavioural therapy for chest pain.
Table 4 Mean (SD) total cost (£) of service used over 12 months follow-up
Standard (n=25) CBT-CP (n=25) Difference* 95% CI, p-value
Mean (SD) Mean SD
CBT intervention 0 0 480.48 293.52
Hospital costs 3403.48 6912.63 1631.96 2299.02
Community costs 236.47 687.18 109.69 195.72
Cardiac and psychotropic drug costs 44.75 96.37 87.20 137.60
Total cost 3732.02 7346.85 2235.53 2434.86 −315.19 (−2782.69 to 2152.31), 
0.798
*Adjusted for baseline cost.
CBT, cognitive behavioural therapy; CBT-CP, CBT for chest pain.
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from current symptoms. These additional problems 
also complicated the length of the CBT-CP treatment so 
that most patients completed their treatment between 
3 months and 6 months after randomisation. This may 
have been a factor in both the delayed improvement at 6 
months and better outcomes at 12 months, so setting this 
study apart from previous ones.
This combined medical and psychological morbidity may 
have been more pronounced in the population of repeat 
attenders in the COPIC Study but is highly relevant both 
to continuing research in this area and to service provision. 
Future studies have to take into account several factors. 
Non-cardiac chest pain is inadequately treated at present 
and is associated with considerable morbidity, signifi-
cant costs and poor outcomes.27 28 As the costs of care for 
physical disease are so much greater than those for the 
management of psychological problems, a marked saving 
could be made in a successful treatment programme.
In 1997 Mayou et al completed one of the early trials 
of CBT for non-cardiac chest pain in patients attending 
a cardiac clinic.29 Their findings are of interest because 
they adumbrated much of subsequent publication on the 
subject. After careful screening of 90 subjects they found 
56 to be eligible but of these only 37 took part, with 60% 
completing all assessments at 12 months. This reluctance, 
according to the authors, ‘reflected the particular prob-
lems of introducing a psychological treatment to patients 
who had been referred to cardiologists with presumptive 
cardiac diagnoses’. This ‘abrupt change in clinical direc-
tion’ was clearly not acceptable to many patients. Mills 
and Mayou30 followed this subject up shortly afterwards 
in a series of editorials in this journal, and, while acknowl-
edging that ‘it may well be difficult for cardiologists who 
are already hard pressed in providing cardiac assessments 
and investigations to consider spending more time on 
the issues covered in these editorials’, they pointed to the 
possible benefits, lying ‘in prevention of heart disease, 
routine clinical care, and the identification and treat-
ment of disabling complications’.
Unfortunately, in the succeeding years, with the growth of 
rapid access chest pain clinics and much greater awareness 
of cardiac pathology fostered by the internet, psychological 
aspects have retreated a little, and it is likely that reluc-
tance of both clinicians to offer psychological therapies 
and patients to accept them will increase unless there is 
a major change in thinking. Now that health anxiety and 
some other persisting types of anxiety have been shown to 
have adverse effects on cardiac outcome5 6 there is a need 
for a new approach involving integration of psychological 
assessment and treatment in cardiac teams such as those 
introduced by Chambers et al31 to achieve better cardiac 
outcomes as well as address healthcare use in those with 
non-cardiac pain.
This might mean that patients are recruited to such 
studies in primary rather than secondary care, as in the 
primary care setting there is less pressure on practitioners 
to be absolutely sure they have excluded physical disease. 
Further studies in secondary care would be best focused 
on the group with the following inclusion criteria:-
A. persistent or recurrent chest pain over a period of 
at least 6 months,
B. repeated negative evidence of relevant physical 
pathology by examination and laboratory 
investigations (eg, negative troponin tests),
C. psychological assessment by a combination of 
rating scales such as those used in this study11–15 
as well as face-to-face assessment, to confirm 
psychopathology of anxiety, depression and 
somatic symptomatology.
Similar psychological assessments have been used in 
cancer services with good effect on outcomes.32 Better 
screening to firm up the exclusion of those who have 
other psychopathology is probably needed also.
Our findings, and the collective view of other studies, 
support comprehensively the notion that in secondary care, 
a multidisciplinary team including cardiologists, psychol-
ogists and nurses, preferably linked to rapid access chest 
pain clinics, should become a stepped care standard.33 It 
is not going to be satisfactory to refer patients for psycho-
logical treatment unless the mental sets and attitudes of 
the referring agencies are able to impart to the patient 
the likely benefits of a different approach to manage-
ment, and without a strong medical component to the 
team other disorders such as oesophageal reflux may be 
wrongly referred for psychological input. In previous work 
we have found that general nurses can be highly effective 
in changing attitudes as well as providing treatment34 and 
when other members of the clinical team are all consistent 
in promoting biosocial alternatives for chest pain, adher-
ence to treatment is likely to be much greater. In the linked 
study in Christchurch, New Zealand, much greater levels 
of recruitment were achieved as the project was nicely 
Table 5 EQ-5D utility score and QALYs over 12 months follow-up
Standard CBT Difference* 95% CI, p value
Mean (SD) Mean (SD)
Utility baseline (n=68) 0.62 0.25 0.65 0.29
Utility 6 months (n=56) 0.78 0.21 0.76 0.20
Utility 12 months (n=52) 0.78 0.22 0.86 0.23
QALY (n=52) 0.74 0.19 0.76 0.19 0.004 (−0.07 to 0.07), 0.900
CBT, cognitive behavioural therapy; QALY, quality adjusted life year.
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encapsulated as a ‘healthy heart’ intervention; this neatly 
joins up psychological and physical aetiologies.
What was also clear from the study was that the diag-
nosis of non-cardiac chest pain is a very unsatisfactory 
one as it is so heterogeneous, and this heterogeneity 
was emphasised by recruitment from both accident and 
emergency clinics and cardiology ones. This problem 
cannot be overcome by a simple screening procedure 
such as a questionnaire as no instrument would be 
able to disentangle the different causes. This hetero-
geneity probably reduced the efficacy of CBT-CP 
in reducing symptoms but the benefits in terms of 
reduced outpatient, inpatient and accident and emer-
gency attendances, were nonetheless substantial. It 
also suggests that more general measures than specific 
symptoms, such as quality of life measured perhaps in 
greater depth than the EQ-5D such as the SF-6D (Short-
Form Six-Dimension),35 might be a better choice of 
primary outcome. With the current demands for finan-
cial savings on all publicly funded health services, the 
economic benefits of introducing such a service are very 
persuasive. Common sense suggests a multidisciplinary 
medicopsychological team is better able to carry out this 
assessment than any other, and a large proportion of 
patients will need only very limited input to make a good 
recovery. The remainder could receive an intervention 
similar to CBT-CP to address the many complex factors 
that reinforce chest pain in vulnerable individuals.
CONCLUSIONS
The combination of limited clinical improvement 
becoming amplified over time, together with possible 
economic gains, in this trial suggests that CBT-CP could be 
a cost-effective treatment for non-cardiac chest pain, but 
changes in service configuration, mental health literacy 
in hospitals and a different recruitment strategy are 
necessary to achieve its maximum benefit. An integrated 
service to assess both medical and mental pathology is 
considered necessary for progress to be made.
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